Reliable Data You Can Trust
Reliable Data You Can Trust
A recent report published by Infinium Global Research on the T cell
immunotherapy market provides an in-depth analysis of segments and sub-segments in
the global as well as regional T cell immunotherapy market. The study also
highlights the impact of drivers, restraints, and macro indicators on the
global and regional T cell immunotherapy market over the short term as well as
long term. The report is a comprehensive presentation of trends, forecast, and
dollar values of the global T cell immunotherapy market. According to the
report, the global T cell immunotherapy market was nearly worth USD 3188.9
million in 2020 and is expected to reach USD 7648.9 million by 2026, growing
with a CAGR of 15.7% over the forecast period of 2020-2026.
According to the WHO, Cancer is the second leading cause of death
globally and is likely to account for 9.6 million death in 2018. T-Cell
immunotherapy is the type of therapy in that cancer is treated by boosting the
immune system in both children as well as adults. T-Cell is the white blood
cells in the immune system that fight infection. In T-cell immunotherapy, the
T-Cells are reprogrammed so they try to find and destroy the cancer cells
present in the body. Each changed or reprogramed T-Cell injected into the body
can multiply into thousands of new ones and stay in the body to keep killing
cancer cells. Therefore, this therapy is also called a “living drug” in cancer
treatment.
The growing occurrence of cancer in both children as well as in
adults creates a huge demand for effective treatments. The rising incidence of
cancer across the globe is a key factor driving the growth of the T-cell
immunotherapy market. Reliable and effective treatments offered by the T-Cell
with the minimum side effects as compared to the other traditional therapies
are contributing to the growth of the T-cell immunotherapy market. In addition,
ongoing development to improve the existing therapies and rising innovations
to provide more effective therapy options are anticipated to boost the growth
of the T-cell immunotherapy market. However, the neurological problems
associated with T-Cell immunotherapy is expected to be the restraining factor
in the T-Cell immunotherapy market. Moreover, various health organizations and
government agencies are taking the initiative to find effective therapy to
treat cancer. The rapidly increasing research and development activities and
technological advancement in cancer treatment are projected to create several
opportunities for the T-Cell immunotherapy market in upcoming years.
Furthermore, the food and drug administration (FDA) has approved CAR T-cell
therapy, axicabtagene ciloleucel (Yescarta), for the treatment of diffuse large
B-cell lymphoma (DLBCL) and CAR T-cell therapy tisagenlecleucel (Kymriah) to
treat cancer in children and adults.
Geographically, North America held the maximum market share in the
T-Cell Immunotherapy market owing to the rising occurrence of cancer. The
developed healthcare infrastructure of North America contributes to the growth
of the T-cell Immunotherapy market. In addition, Asia-Pacific is the
fastest-growing region in T-Cell Immunotherapy. The developing healthcare
infrastructure, growing geriatric population, and rising occurrence of cancer
are the primary factors driving the growth of the T-Cell Immunotherapy market
in the Asia-Pacific region.
The report on global T cell immunotherapy market covers segments
such as mechanism of action, type of therapy, and product class. On the basis
of mechanism of action, the sub-markets include active immunotherapy, and
passive immunotherapy. On the basis of type of therapy, the sub-markets include
CAR-T, TCR, and TIL. On the basis of product class, the sub-markets include
monoclonal antibodies, oncolytic virus therapy, bispecific antibodies, and
cytokines.
The report provides profiles of the companies in the market such
as Adaptimmune Therapeutics, Bluebird Bio, Innovative Cellular Therapeutics,
Novartis, Sinobioway Cell Therapy, Cellectis, CARsgen Therapeutics, Autolus
ltd, Celgene, and Others.
The report provides deep insights into the demand forecasts,
market trends, and micro and macro indicators. In addition, this report
provides insights into the factors that are driving and restraining the growth
in this market. Moreover, The IGR-Growth Matrix analysis given in the report
brings an insight into the investment areas that existing or new market players
can consider. The report provides insights into the market using analytical
tools such as Porter's five forces analysis and DRO analysis of the T cell
immunotherapy market. Moreover, the study highlights current market trends and
provides forecast from 2020-2026. We also have highlighted future trends in the
market that will affect the demand during the forecast period. Moreover, the
competitive analysis given in each regional market brings an insight into the
market share of the leading players.
Please Choose One of them.